Dan Stanton is an Editor at Informa Connect. He focuses on themes related to manufacturing and manufacturing technology, providing insights into the latest trends and innovations in these critical sectors. Dan's work has been featured in BioProcess International, showcasing his expertise and contributions to the industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
Dan Stanton's coverage primarily focuses on press releases and private sector announcements in the healthcare, pharmaceutical, biotechnology, and manufacturing industries. He often covers topics such as biotechnology advancements, drug development, manufacturing expansions, and investment deals within these sectors.
Given his focus on industry-specific announcements and news from private companies, Dan may be interested in pitches related to exclusive interviews or insights from key figures within the mentioned industries. If you can provide unique perspectives or insider views related to new developments in drug manufacturing technologies or significant investment deals within the pharmaceutical sector, it is likely to align with his coverage interests.
As there is no specific geographic focus mentioned for Dan Stanton's articles, outreach efforts should emphasize global relevance rather than a regional perspective.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Dan Stanton
Moving away from fed-batch has significant sustainability and cost-saving benefits, according to industry working groups.
By: Dan Stanton
Process intensification has reduced the cost of mAb manufacturing, but tweaks across bioproduction will be needed to reduce price-per-gram further.
By: Dan Stanton
Regulatory fragmentation, language barriers, and the absence of basic supplier filing mechanisms are holding back cell and gene therapy (CGT) development in Europe.
